The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients |
|---|---|
| Study Drug | MP-376 (Levofloxacin Solution for Inhalation) |
| Type of Study Drug | Anti-infective |
| Study Title | Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients. |
| Study Phase | 3 |
| Study Sponsor | Mpex Pharmaceuticals |
http://clinicaltrials.gov/ct2/show/NCT01270347 (link is external) | |
| Participating ECFS-CTN sites | Germany: Berlin, Frankfurt, Munich France: Montpellier, Bordeaux/Toulouse, West-Paris UK: Belfast, Birmingham, Leeds, Nottingham |
| Age | 12 years and older |